January 30, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into TransMedics Group, Inc. (NASDAQ: TMDX) for potential violations of the federal securities ...

New York, New York-- (Newsfile Corp. - January 29, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into TransMedics Group, Inc. (NASDAQ: TMDX) for potential ...

Harmony Biosciences' Wakix shows promise for significant revenue growth. Find out why HRMY stock’s profitability and pipeline ...

Shares of TransMedics, Group Inc. (NASDAQ: TMDX) suffered a sharp decline over the past two trading days following the release of a ...

TransMedics Group, Inc. TMDX recently issued a statement refuting the claims made in a report by short-seller Scorpion Capital on Jan. 10, 2025, stating them as inaccurate and misleading.

Eli Lilly has announced plans to acquire Scorpion Therapeutics’ PI3Kα inhibitor program. Credit: Michael Vi via Shutterstock. Eli Lilly will buy Boston biotech Scorpion Therapeutics’ PI3Kα inhibitor ...

We maintain cautious stance on TransMedics investment due to high-risk factors. Read here for an analysis of TMDX stock drop and future prospects.

Shares of organ transplant innovator TransMedics Group ( TMDX -1.41%) fell 15.7% through Thursday trading, according to data from S&P Global Market Intelligence. TransMedics was the target of an ...

The claims, detailed in a report by short-seller Scorpion Capital, have triggered investigations by two shareholder rights law firms. In response, TransMedics has issued a strong denial ...

On January 10, 2025, before the market open, Scorpion Capital announced on X that it was "short $TMDX TransMedics, " issued a reported titled "Walk Like An Egyptian ...

Scorpion Capital alleges that the NOP operates as an "unsustainable, anti-competitive scheme" involving coercive tying, price extortion, and retaliation. The report further claims the NOP ...